Migkos Michalis P, Kaltsonoudis Evripidis, Pelechas Eleftherios, Drossou Vassiliki, Karagianni Panagiota G, Kavvadias Athanasios, Voulgari Paraskevi V, Drosos Alexandros A
Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, 45110, Ioannina, Greece.
Laboratory Medicine, Department of Microbiology, Medical School, University of Ioannina, 45110, Ioannina, Greece.
Rheumatol Int. 2021 May;41(5):903-909. doi: 10.1007/s00296-021-04818-2. Epub 2021 Mar 3.
To examine whether patients with inflammatory arthritis (IA) treated with conventional synthetic (cs) disease-modifying anti-rheumatic drugs (DMARDs) and/or biologic (b) DMARDs, could be affected from SARS-CoV-2 infection and to explore the COVID-19 disease course and outcome in this population. This is a prospective observational study. During the period February-December 2020, 443 patients with IA who were followed-up in the outpatient arthritis clinic were investigated. All patients were receiving cs and/or bDMARDs. During follow-up, the clinical, laboratory findings, comorbidities and drug side effects were all recorded and the treatment was adjusted or changed according to clinical manifestations and patient's needs. There were 251 patients with rheumatoid arthritis (RA), 101 with psoriatic arthritis (PsA) and 91 with ankylosing spondylitis (AS). We identified 32 patients who contracted COVID-19 (17 RA, 8 PsA, 7 AS). All were in remission and all drugs were discontinued. They presented mild COVID-19 symptoms, expressed mainly with systemic manifestations and sore throat, while six presented olfactory dysfunction and gastrointestinal disturbances, and all of them had a favorable disease course. However, three patients were admitted to the hospital, two of them with respiratory symptoms and pneumonia and were treated appropriately with excellent clinical response and outcome. Patients with IA treated with cs and/or bDMARDs have almost the same disease course with the general population when contract COVID-19.
为了研究接受传统合成（cs）改善病情抗风湿药物（DMARDs）和/或生物（b）DMARDs治疗的炎症性关节炎（IA）患者是否会受到严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染的影响，并探索该人群中冠状病毒病（COVID-19）的病程和结局。这是一项前瞻性观察性研究。在2020年2月至12月期间，对在门诊关节炎诊所接受随访的443例IA患者进行了调查。所有患者均接受cs和/或bDMARDs治疗。在随访期间，记录所有临床、实验室检查结果、合并症和药物副作用，并根据临床表现和患者需求调整或改变治疗方案。其中类风湿关节炎（RA）患者251例，银屑病关节炎（PsA）患者101例，强直性脊柱炎（AS）患者91例。我们确定了32例感染COVID-19的患者（17例RA，8例PsA，7例AS）。所有患者病情均缓解，所有药物均停用。他们表现出轻度COVID-19症状，主要表现为全身症状和咽痛，6例出现嗅觉功能障碍和胃肠道不适，所有患者病程均良好。然而，3例患者入院，其中2例有呼吸道症状和肺炎，经适当治疗后临床反应和结局良好。接受cs和/或bDMARDs治疗的IA患者感染COVID-19时的病程与普通人群几乎相同。
